Metformin—mode of action and clinical implications for diabetes and cancer

By I. Pernicova, M. Korbonits. Nature Reviews Endocrinology, 2014

1,235 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/b0aaaa464852e83365c249b05b55a686078d766f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Ralph DeFronzo
2. I. Tabas
3. K. Bornfeldt

In Molecular Biology

1. Ralph DeFronzo
2. P. Scherer
3. K. Bornfeldt
4. I. Tabas

In Surgery

1. Ralph DeFronzo
2. P. Scherer

Citations in the corpus

• Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut (2016, background): “Metformin (1,1-dimethylbiguanide hydrochloride) is the most frequent medication used to treat type 2 diabetes (7), and findings from recent studies suggest it may also prevent cancer (7) and cardiovascular events (8).”
• Metformin-associated lactic acidosis: Current perspectives on causes and risk. (2016, background): “metformin, have a reduced threshold for the development of lactic acidosis in response to a secondary event [19,25,26,41].”
• Shared Risk Factors in Cardiovascular Disease and Cancer (2016, background): “Metformin has been thought to reduce the risk of cancer and has a plausible biological mechanism, although population studies have demonstrated mixed results.(85,86) Metformin activates adenosine monophosphate– activated protein kinase in hepatocytes, a major cellular regulator of lipid and glucose ”
• Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis Through Adipose Tissue Crosstalk (2016, background): “Treatments that enhance systemic insulin sensitivity have been shown to enhance glucose uptake by peripheral tissues while decreasing hepatic glucose output (Pernicova and Korbonits, 2014).”
• Metformin in patients with type 2 diabetes and kidney disease: a systematic review. (2014, neutral): “Thus, the final number of manuscripts was 65 (pharmacokinetic/ metabolic investigations [10]; case series [20]; cross-sectional, observational, and pharmacosurveillance studies [31]; metaanalyses [3]; and a clinical trial [1]).”
• Metformin promotes antitumor immunity via endoplasmic reticulum-associated degradation of PD-L1 (2018, neutral): “Metformin has been shown to directly induce antitumor effects by inhibiting the PI3K (phosphatidylinositol 3-kinase)-AktmTOR and Ras-MAPK (mitogen-activated protein kinase) signaling pathways critical for cancer progression or indirectly by systemically reducing glucose and insulin metabolism to att”